Document is current
Any future updates will be listed below
-
Authors
Lima, João Pedro https://orcid.org/0000-0002-5486-7211
Zeraatkar, Dena
Matos Silva, Jessyca
Carciumaru, Briana
Steel, David H. https://orcid.org/0000-0001-8734-3089
Wong, Tien Yin https://orcid.org/0000-0002-8448-1264
Wykoff, Charlie C.
Chaudhary, Varun https://orcid.org/0000-0002-9988-4146
,
Bhandari, Mohit
Wykoff, Charles C.
Sivaprasad, Sobha
Thabane, Lehana
Kaiser, Peter
Sarraf, David
Bakri, Sophie J.
Garg, Sunir J.
Singh, Rishi P.
Holz, Frank G.
Wong, Tien Y.
Guymer, Robyn H.
Steel, David H.
Sadda, SriniVas R.
- License Information
-
More Information
Article History
Received: 25 September 2025
Revised: 13 October 2025
Accepted: 17 November 2025
First Online: 9 December 2025
Competing interests
: JPL: None. DZ: None. JMS: None. BC: None. DHS: Consultant for Alcon, BVI, DORC, Roche, Alimera, Eyepoint, Complement Therapeutics, Sitala, AviadoBio; Research funding: Alcon, Bayer, DORC, BVI, Boehringer-Ingelheim. TYW: TYW is a consultant for Astellas, Bayer, Boehringer-Ingelheim, Genentech, Iveric Bio, Novartis, Oxurion, Plano, Roche, Sanofi, and Shanghai Henlius. He is an inventor, holds patents and is a co-founder of start-up companies EyRiS and Visre, which have interests in and develop digital solutions for eye diseases. CCW: CCW reports consulting for 4DMT, AbbVie, Adverum, Alcon, Alimera, Alkeus, Annexon, Apellis, Aviceda, Bayer, Biocryst, Boehringer Ingelheim, Clearside, EyeBiotech, EyePoint, Genentech, InGel, Janssen, Kiora, KodiakMerck, Neurotech, Novartis, Ocuphire, ONL, Opthea, Osanni, Panther, Perceive Bio, Ray, Regeneron, RegenXBio, Sanofi, Santen, Stealth, Valo, Zeiss. VC: VC reports acting as an advisory board member, grants and other from Novartis; acting as an advisory board member, grants and other from Bayer; grants from Allergan; acting as an advisory board member and grants from Roche; acting as an advisory board member for Janssen; acting as an advisory board member for Apellis; acting as an advisory board member for Boehringer Ingelheim, and acting as an advisory board member for EyePoint outside the submitted work.
Free to read: This content has been made available to all.
